Biotest AG

  • WKN: 522723
  • ISIN: DE0005227235
  • Land: Deutschland

Nachricht vom 17.02.2017 | 13:30

Biotest AG: Proceedings against Biotest AG have been closed

DGAP-News: Biotest AG / Key word(s): Legal Matter

17.02.2017 / 13:30
The issuer is solely responsible for the content of this announcement.


/
PRESS RELEASE

Proceedings against Biotest AG have been closed

Dreieich, 17 February 2017. Biotest AG has agreed with the Frankfurt public prosecution on a mutual termination of the proceedings against the company due to the Russia business.

Besides the tax payment already communicated on 4 November 2016, Biotest has paid a corporate fine in the amount of EUR1.0 million. Thereby proceedings against Biotest are closed. Since a provision for this amount has already been recognised in financial year 2016, the payment has no effect on the result in the 2017 financial year.

The public prosecution has moreover ceased investigation proceedings against several employees of the company.

Proceedings against three managers of Biotest AG, including the CFO, continue. The public prosecution has meanwhile filed charges with the competent court due to breach of trust, bribery and tax evasion. It has not yet been decided whether the charges will be admitted.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



17.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Rock Tech: Profiteuer des E-Mobility-Booms

Rock Tech ist eine Rohstoff-Beteiligungsgesellschaft mit dem Schwerpunkt auf Assets im Lithium-Bereich. Lithium ist ein wesentlicher Bestandteil von modernen Batterien, die bspw. in elektronischen Fahrzeugen eingesetzt werden. Hierdurch profitiert das Unternehmen sehr stark vom E-Mobility-Boom. Parallel hierzu beflügelt der stark ansteigende Lithiumpreis. Mit dem Kern-Asset Georgia Lake verfügt man bereits über fast 10 Mio. Tonnen an NI-konformen lithiumhaltigen Ressourcen. Da es sich hierbei um ein Gebiet mit reichem Vorkommen handelt, gehen wir davon aus, dass in naher Zukunft die aktuelle Ressourcenbasis deutlich ausgebaut werden kann und sich damit der Unternehmenswert deutlich erhöhen könnte. Aufgrund der guten Rahmenbedingungen sehen wir den fairen Wert je Aktie bei 1,47 EUR (akt. Kurs: 0,68 €) und damit ein Potenzial von über 100%. Vor diesem Hintergrund vergeben wir das Rating KAUFEN.

News im Fokus

Linde AG: Vorstand und Aufsichtsrat der Linde AG empfehlen Annahme des Tauschangebots der Linde plc

21. August 2017, 13:12

Aktueller Webcast

ADO Properties S.A.

HALF - YEAR RESULTS 2017

17. August 2017

Aktuelle Research-Studie

Grand City Properties S.A.

Original-Research: GRAND CITY Properties S.A. (von First Berlin Equity Research GmbH): BUY

22. August 2017